Phase 2 Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Phase 1
Who might be able to join this trial:
- People aged between 18 and 65 years old
- People who are generally healthy with no significant medical history
- People who are able and willing to attend all scheduled study visits and follow the study requirements
- People who are willing to sign a written consent form agreeing to take part
Who may not be able to join:
- People who have a significant health condition or disease
- People who have a physical or mental health condition that would prevent them from completing the study
- People with a known history of illegal drug use, drug abuse, harmful alcohol use, alcoholism, or use of tobacco or nicotine products in the 3 months before the first study dose
- People who have had severe allergic reactions or serious sensitivities in the past
- People who have donated or lost one unit or more of blood or plasma in the 2 months before dosing
Phase 2a
Who might be able to join this trial:
- People aged between 18 and 65 years old
- People who are generally healthy with no significant medical history
- People who are able and willing to attend all scheduled study visits and follow the study requirements
- People who are willing to sign a written consent form agreeing to take part
- People who have had a documented asthma diagnosis for at least 12 months before the screening visit
- People who are currently experiencing asthma symptoms
- People who are currently taking regular asthma maintenance medication
Who may not be able to join:
- People who have a significant health condition or disease
- People with a known history of illegal drug use, drug abuse, harmful alcohol use, alcoholism, or use of tobacco or nicotine products in the 3 months before the first study dose
- People who have donated or lost one unit or more of blood or plasma in the 2 months before dosing
- People who have had severe allergic reactions or serious sensitivities in the past
- People who have smoked 10 or more pack-years (confirm with trial site for clarification on how this is calculated)
- People who have received immune-suppressing medications or biologic treatments for asthma within 6 months before the screening visit
- People who have taken part in another clinical trial and received an investigational treatment within 30 days before dosing
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +61 (0)8 6382 5110
Australian sites
0289648186
0395096166
011 61 88 6382 5110
08 6382 5110
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) with a single dose of PRA-216 in healthy volunteers (SAD arm); Phase 1: Incidence, nature, and severity of serious adverse events (SAEs) of multiple doses of PRA-216 in healthy volunteers (MAD arm); Phase 2a: To evaluate the effect of multiple doses of PRA-216 compared to placebo on exhaled nitric oxide (FeNO) in asthma participants
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.